![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, December 04, 2021 5:48:57 PM
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.
"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.
https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html
Recent OGEN News
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients • GlobeNewswire Inc. • 08/21/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 12:30:09 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/16/2024 08:45:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:30:15 PM
- Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 08/16/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:30:38 PM
- Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:30:14 PM
- Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study • GlobeNewswire Inc. • 08/12/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:30:43 PM
- Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing • GlobeNewswire Inc. • 08/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:30:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 08:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 12:00:30 PM
- Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Oragenics Develops Automated Intranasal Device for Treating Concussed Patients • GlobeNewswire Inc. • 06/27/2024 12:30:40 PM
- Oragenics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 06/26/2024 08:47:15 PM
- Oragenics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
- Oragenics, Inc. Announces Proposed Public Offering • GlobeNewswire Inc. • 06/24/2024 10:43:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:24 PM
- Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 01:27:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:17 PM
- Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:00:41 PM
FEATURED ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM